首页> 外文OA文献 >Locoregional treatment of low-grade B-cell lymphoma with CD3�CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

【2h】

Locoregional treatment of low-grade B-cell lymphoma with CD3�CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

机译：低级B细胞淋巴瘤的招诊疗与CD3�CD19双特异性抗体和CD28共刺激：I.临床阶段I评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Oliver Manzke; Hans Tesch; Peter Borchmann; J�rgen Wolf; Klaus Lackner; Axel Gossmann; Volker Diehl; Heribert Bohlen;
展开▼
作者单位

展开▼
年度 2001
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study [J] . Budde Lihua E., Sehn Laurie H., Assouline Sarit, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：MosuneTuzumab，全长双特异性CD20 / CD3抗体，在复发/难治性B细胞非霍奇金淋巴瘤（NHL）中显示临床活性：临时安全性和疗效结果来自阶段1研究
2. Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202) [J] . Sawas Ahmed, Elgedawe Hager, Vlad George, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：CD30 / CD16A四价双特异性抗体（AFM13）的临床和生物学评价，复发或难治性CD30阳性淋巴瘤与皮肤介绍：生物标志物Ia IA研究（NCT03192202）
3. A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma [J] . Lesokhin Alexander M., Raje Noopur, Gasparetto Cristina J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：I阶段，开放标签研究，评估PF-06863135的安全性，药代动力学，药效和临床活性，B细胞成熟抗原/ CD3双特异性抗体，复发/难治性先进的多发性骨髓瘤患者
4. A CD19/CD3 Bispecific TandAb, AFM11, Recruits T Cells to Potently and Safely Kill CD19+ Tumor Cells in Pre-Clinical Models [C] . Uwe Reusch, Stefan Knackmuss, Kristina Ellwanger, PEGS . 2014

机译：CD19 / CD3双特异性TANDAB，AFM11，在临床前模型中促进T细胞才能效果，安全地杀死CD19 +肿瘤细胞
5. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
6. Immunotherapy with FBTA05 (Bi20) a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven open-label non-randomized uncontrolled dose-escalating Phase I/II-trial [O] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案非随机不受控制剂量递增的I / II试验阶段
7. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies [O] . H Bohlen, T Hopff, O Manzke, 1993

机译：通过用CD3 X CD19双特异性抗体激活B-慢性淋巴细胞白血病患者来自B-慢性淋巴细胞白血病患者的恶性B细胞的裂解，与二价CD28抗体组合

Locoregional treatment of low-grade B-cell lymphoma with CD3�CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation

著录项

引文网络

相似文献

相关主题

期刊订阅